Ad-hoc | 1 March 2001 08:17

Ad hoc-Service: EVOTEC BioSystems AG english

Ad-hoc announcement precessed and sent by DGAP. The sender is solely responsible for the contents of this announcement. ——————————————————————————– EVOTEC OAI Signs TWO Chemistry Services Contracts With Lilly Hamburg, Germany/Abingdon, UK, 1 March 2001 – EVOTEC OAI, Hamburg, Germany (EVOTEC BioSystems AG, Neuer Markt: EVT) has secured two contracts with Eli Lilly and Company (NYSE: LLY), a world leading pharmaceutical company. The two contracts span the provision of chemistry services by EVOTEC OAI to Lilly across drug discovery for the first and process research and development for the second. Each contract covers an initial fixed term of one year with an option to extend. The details of each contract are outlined below: Discovery Services Agreement Within this Discovery Services Agreement, EVOTEC OAI will provide a team of dedicated Full Time Equivalent (FTE) chemists to work exclusively on the design and synthesis of compounds for lead generation, validation as well as lead optimisation for key drug candidates to be included in Lilly’s discovery pipeline. Development Services Agreement The Development Services Agreement has a second team of FTE chemists dedicated exclusively to Lilly process research and development projects. The Agreement also calls for EVOTEC OAI to subsequently scale up in its cGMP facilities several of Lilly’s active pharmaceutical ingredients (APIs) for use in clinical trials. In total, 18 FTEs are contracted to Lilly in these two agreements. EVOTEC BioSystems AG Anne Hennecke, Investor Relations Phone: +49-40-56081286 Fax: +49-40-56081222 E-mail: anne.hennecke@evotec.de end of Ad hoc-announcement, (c) DGAP 01.03.2001 ———————————————————————– WKN: 566480; Index: NEMAX-50 Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 010817 Mär 01